NPY antagonists (Allelix/Lilly)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameNPY antagonists (Allelix/Lilly)
Drug Alias Nameneuropeptide Y antagonists (Allelix/Lilly)LY-357897
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuropeptide Y receptor type 2 antagonistsNeuropeptide Y receptor type 1 antagonists
TargetsNeuropeptide Y receptor type 1Neuropeptide Y receptor type 2
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNps Allelix Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNps Allelix CorpEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsObesityDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A